Treatment for XLH Receives Approval in Switzerland
Kyowa Kirin has announced that its treatment for X-linked hypophosphatemia (XLH), Crysvita (burisumab), has been approved by Swissmedic for use in adults, adolescents, and children (1 year and older).
In a Feb. 21, 2020 press release, Kyowa Kirin has announced that its treatment for X-linked hypophosphatemia (XLH), Crysvita (burisumab), has been approved by Swissmedic for use in adults, adolescents, and children (1 year and older).
XLH is a rare, genetic disease that causes abnormalities in bones, muscles, and joints, and although not life-threatening is recognized to have the potential to reduce quality of life. Crysvita is designed to target the underlying cause of XLH and is expected to be available for prescription in Switzerland as per the provisions of Article 71 of the KVV (Verordnung über die Krankenversicherung).
“XLH is the most common form of hereditary rickets,” said Abdul Mullick, president of Kyowa Kirin International, in the press release. “Many patients experience debilitating symptoms on a daily basis, including joint and bone pain, stiffness, and fatigue, and may have trouble walking. Bringing this important treatment to adults and children with XLH in Switzerland is a very important milestone for our company and for the treatment of this rare, progressive disease.”
“Crysvita (burosumab) is the first and only treatment available in Switzerland for patients with XLH that targets the underlying cause of the disease,” added Tomohiro Sudo, head of Global Product Management Office of Kyowa Kirin, in the press release. “We are proud that Crysvita is now available to patients in Switzerland and we are continuing our work to broaden the treatment options for more patients with XLH around the world.”
Source: Kyowa Kirin
